

Oncology Drugs in the Pipeline

HEM Onc TODAY's annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. To view the entire chart online, go to www.healio.com/oncologypipeline.

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
177Lu-DOTA-Octreotide (Lutathera, Advanced Accelerator Applications)	pancreatic neuroendocrine tumors	phase 3
177Lu-J591 (BZL Biologics)	prostate cancer	phase 2
A6 (Angstrom Pharmaceuticals)	ovarian cancer	phase 2
abagovomab (Menarini)	ovarian cancer	phase 3
abexinostat (Pharmacyclics)	follicular lymphoma, mantle cell lymphoma	phase 2
ABT-199 (AbbVie)	acute myeloid leukemia/chronic lymphocytic leukemia	phase 2/phase 3
ACE-536 (Acceleron Pharma/Celgene)	anemia in myelodysplastic syndrome	phase 2
ACY-1215 (Acetylon Pharmaceuticals)	myeloma	phase 2
ADI-PEG 20 (Polaris)	melanoma/hepatocellular melanoma	phase 2/phase 3
ado-trastuzumab emtansine (Kadcyla, Genentech)	breast cancer, gastric cancer	phase 3
ADXS-HPV (Advaxis)	anal cancer, cervical intraepithelial neoplasia, recurrent cervical cancer	phase 2
AE37 (Antigen Express)	breast cancer, prostate cancer	phase 2
AEZS-108 (Aeterna/Zentaris)	ovarian cancer, pancreatic cancer, prostate cancer/endometrial cancer	phase 2/phase 3
afatinib (BIBW 2992, Boehringer Ingelheim)	head and neck cancers	phase 3
afimoxifene (Ascend Therapeutics)	breast cancer	phase 2
AFP464 (Kirax)	breast cancer	phase 2
afuresertib (GlaxoSmithKline)	ovarian cancer	phase 2
AGS-003 (Argos Therapeutics)	metastatic kidney cancer/first-line kidney cancer	phase 2/phase 3
albumin-bound paclitaxel (Abraxane, Celgene)	breast cancer, melanoma, pancreatic cancer	phase 3
acolbifene (EndoCeutics)	breast cancer	phase 2
aldoxorubicin (CytRX)	pancreatic adenocarcinoma, soft tissue sarcoma	phase 2
algenpantucel-L (HyperAcute Pancreas, NewLink Genetics)	pancreatic cancer	phase 3
alisertib (MLN8237, Millennium Pharmaceuticals)	hematologic malignancies, solid tumors/peripheral T-cell lymphoma	phase 2/phase 3
AlloStim (Immunovative Therapies)	hematologic malignancies, solid tumors	phase 2
ALT-801 (Altor BioScience)	melanoma, myeloma, urogenital cancer	phase 2
amatuximab (MORAb-009, Eisai)	mesothelioma	phase 2
AMG 386 (Millennium)	ovarian cancer	phase 3
aminolevulinic acid (Levulan PDT, DUSA Pharmaceuticals)	brain cancer	phase 2
aminopterin (Syntrix Biosystems)	pediatric acute lymphoblastic leukemia	phase 2
amuvatinib (MP470, Astex Pharmaceuticals)	small cell lung cancer	phase 2
anti-CD45 mAb (Iomab-B, Actinium)	acute myeloid leukemia	phase 2
anti-HER3/EGFR DAF MAb (Genentech)	colorectal cancer, head and neck cancers	phase 2
anti-MUC1 mAb (Quest PharmaTech)	pancreatic cancer	phase 2
anti-NaPi2b antibody drug conjugate (Genentech)	ovarian cancer	phase 2
antigen cancer vaccine (MVA-BN Pro, BN ImmunoTherapeutics)	prostate cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
antisense oligonucleotide (Archexin, Rexahn)	pancreatic cancer	phase 2
AP1903 (Bellicum Pharmaceuticals)	prostate cancer	phase 2
AP26113 (Ariad)	non-small cell lung cancer	phase 2
AP5346 (Access Pharmaceuticals)	head and neck cancers	phase 2
apaziquone (EOquin; Allergan, Spectrum Pharmaceuticals)	bladder cancer	phase 3
APC-100 (Adamis Pharmaceuticals)	prostate cancer	phase 2
APN301 (Apeiron Biologics/NCI)	melanoma, neuroblastoma	phase 2
apricoxib (TG01, Tragara Pharmaceuticals)	non-small cell lung cancer, pancreatic cancer	phase 2
ARC-100 (Archer Biosciences)	breast cancer, glioma, glioblastoma, melanoma, neuroblastoma, prostate cancer	phase 2
ARN-509 (Aragon Pharmaceuticals)	prostate cancer	phase 2
ARQ 197 (ArQule)	microphthalmia transcription factor tumors	phase 2
ARX-02 (AcelRx Pharmaceuticals)	cancer pain	phase 2
ascorbic acid/menadione (Apatone, IC-MedTech)	prostate cancer	phase 2
ASG-15ME (Seattle Genetics)	bladder cancer	phase 2
ASG-22ME (Seattle Genetics)	solid tumors	phase 2
ASLAN001/ARRY-543 (Aslan Pharmaceuticals/Array BioPharma)	solid tumors	phase 2
ASTX727 (Astex Pharmaceuticals)	myelodysplastic syndrome	phase 2
AT-101 (Ascenta Therapeutics)	chronic lymphocytic leukemia, esophageal cancer, glioblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, prostate cancer	phase 2
AT13387 (Astex Pharmaceuticals)	lung cancer, prostate cancer	phase 2
AT7519 (Astex Pharmaceuticals)	myeloma	phase 2
AT9283 (Astex Pharmaceuticals)	myeloma	phase 2
autologous cell vaccine (OVax, AVAX Technologies)	ovarian cancer	phase 2
autologous stem cell therapy (California Stem Cells)	melanoma	phase 2
autologous tumor cell vaccine (FANG vaccine, Gradalis)	colorectal cancer, melanoma, ovarian cancer	phase 2
AUY922 (Novartis)	breast cancer, gastrointestinal stromal tumors, non-small cell lung cancer, myeloma	phase 2
AV0113 (Activartis Biotech)	glioma	phase 2
AVX701 (AlphaVax)	CEA-expressing colorectal cancer	phase 2
axitinib (Inlyta, Pfizer)	liver cancer/renal cell carcinoma	phase 2/phase 3
azacitidine (Vidaza, Celgene)	acute myeloid leukemia	phase 3
AZD1775 (AstraZeneca)	ovarian cancer	phase 2
AZD2014 (AstraZeneca)	solid tumors	phase 2
AZD4547 (AstraZeneca)	solid tumors	phase 2
bafetinib (CytRx)	chronic lymphocytic leukemia, prostate cancer	phase 2
bavituximab (Peregrine Pharmaceuticals)	liver cancer, non-small cell lung cancer, pancreatic cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
BC-819 (BioCancell Therapeutics)	bladder cancer, pancreatic cancer	phase 2
B-cell lymphoma vaccine (BiovaxID, Biovest International)	mantle cell lymphoma/indolent follicular lymphoma	phase 2/phase 3
belagenpumatucel-L (Lucanix, NovaRx)	non-small cell lung cancer	phase 3
belinostat (PXD 101, Spectrum Pharmaceuticals)	peripheral T-cell lymphoma	phase 2
belotecan (OnKor Pharmaceuticals)	solid tumors	phase 2
bendamustine (Treanda, Cephalon)	acute lymphoblastic leukemia, acute myeloid leukemia, mantle cell lymphoma, myeloma	phase 2
bevacizumab (Avastin, Genentech)	breast cancer, carcinoid tumor, cervical cancer, glioblastoma, ovarian cancer, non-small cell lung cancer	phase 3
BGJ398 (Novartis)	glioblastoma, melanoma	phase 2
binimetinib (MEK162; Novartis, Array BioPharma)	various cancers	phase 3
birinapant (TetraLogic)	acute myeloid leukemia	phase 2
BIW-8962 (BioWa/Kyowa Hakko Kirin)	myeloma	phase 2
BKM120 (Novartis)	breast cancer, endometrial cancer, glioblastoma, non-small cell lung cancer, relapsed or refractory non-Hodgkin's lymphoma, urogenital cancer	phase 2
BL-8040 (BioLineRx)	acute myeloid leukemia	phase 2
blinatumomab (AMG 103, Amgen)	non-Hodgkin's lymphoma/acute lymphoblastic leukemia	phase 2/phase 3
BMN-673 (BioMarin Pharmaceuticals)	solid tumors	phase 2
BNC105 (Bionomics)	kidney cancer	phase 2
BNP1350 (Karenitecin, BioNumerik Pharmaceuticals)	non-small cell lung cancer/ovarian cancer	phase 2/phase 3
bortezomib (Velcade, Millennium Pharmaceuticals)	mantle cell lymphoma	phase 3
BPX-101 (Bellicum Pharmaceuticals)	prostate cancer	phase 2
brentuximab vedotin (Adcetris; Millennium Pharmaceuticals, Seattle Genetics)	CD30-positive non-lymphoma malignancies, diffuse large B-cell lymphoma, Hodgkin's lymphoma/CD30-positive cutaneous T-cell lymphoma, CD30-positive mature T-cell lymphomas, Hodgkin's lymphoma	phase 2/phase 3
BT-062 (Biotest Pharmaceuticals/ImmunoGen)	myeloma	phase 2
BYL719 (Novartis)	breast cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma	phase 2
c31510 (Cytotech)	basal cell cancer, squamous cell cancer	phase 2
CA-18C3/MABp1 (XBiotech)	cancer-related cachexia	phase 3
cabazitaxel (Jevtana, Sanofi)	prostate cancer	phase 3
cabozantinib (Exelixis)	breast cancer, non-small cell lung cancer, ovarian cancer/prostate cancer, thyroid cancer	phase 2/phase 3
calaspargase pegol (Sigma-Tau Pharmaceuticals)	acute lymphoblastic leukemia	phase 3
cancer vaccine (Immunitor USA)	cancer	phase 2
cancer vaccine (MabVax Therapeutics)	sarcoma	phase 2
cancer vaccine (NeuVax, Galena Biopharma)	prostate cancer/breast cancer	phase 2/phase 3
canfosfamide (Telik)	non-small cell lung cancer	phase 3
Captisol-enabled melphalan (Spectrum)	myeloma (autologous stem cell transplant conditioning)	phase 2
carfilzomib (Kyprolis, Onyx Pharmaceuticals)	myeloma	phase 3
carlecortemcel-L (StemEx; Gamida Cell, Teva)	hematologic malignancies	phase 3
catumaxomab (Fresenius Biotech North America)	malignant ascites, ovarian cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
CB-10-01 (Cosmo Pharmaceuticals)	melanoma	phase 2
CBP501 (CanBas)	mesothelioma, non-small cell lung cancer	phase 2
CC-486 (Celgene)	lower-risk myelodysplastic syndrome, post-induction acute myeloid leukemia maintenance	phase 2
CD1400 (Canopus BioPharma)	chemotherapy- and radiation-induced mucositis	phase 2
CDX-011 (Celldex Therapeutics)	melanoma	phase 2
CDX-1401 (Celldex Therapeutics)	breast cancer, solid tumors	phase 2
CEP-18770 (Cephalon)	multiple myeloma	phase 2
cetuximab (Erbix, Bristol-Myers Squibb)	gastric cancer, squamous cell carcinoma of the head and neck/colorectal cancer	phase 2/phase 3
CG201 (CG Therapeutics)	solid tumors	phase 2
chimeric monoclonal antibody14.18 (United Therapeutics/NCI)	neuroblastoma	phase 3
cixutumumab (IMC-A12; ImClone, Eli Lilly)	non-small cell lung cancer	phase 2
clofarabine (Clolar, Genzyme)	acute myeloid leukemia	phase 2
CLT-008 (Cellerant Therapeutics)	chemotherapy-related neutropenia	phase 2
CNDO-109 (Coronado Biosciences)	acute myeloid leukemia	phase 2
CO-101 (Clovis Oncology)	pancreatic cancer	phase 2
CO-1686 (Clovis Oncology)	EGFR mutations, non-small cell lung cancer	phase 2
cobimetinib (GDC-0973, Genentech)	melanoma	phase 3
colorectal cancer vaccine (OncoVAX, Vaccinogen)	colorectal cancer (stage III), kidney cancer, melanoma/colorectal cancer (stage II)	phase 2/phase 3
companion diagnostic test EGFR-TKI (VeriStrat, Biodesix)	breast cancer	phase 3
copanlisib (BAY 80-6946, Bayer HealthCare)	non-Hodgkin's lymphoma	phase 2
corticotropin-releasing factor (Xerecept, Celtic Pharma)	brain edema associated with brain tumors	phase 2
corticotropin-releasing factor (Xerecept, Celtic Pharma)	peritumoral brain edema	phase 3
coxsackievirus A21 (Cavatak, Viralytics)	melanoma	phase 2
CP-613 (Cornerstone Pharmaceuticals)	pancreatic cancer	phase 2
CPI-613 (Cornerstone Pharmaceuticals)	pancreatic cancer	phase 2
CPP-1X (Cancer Prevention Pharmaceuticals)	neuroblastoma	phase 2
CPX-1 (Celator Pharmaceuticals)	colorectal cancer	phase 2
CPX-351 (Celator Pharmaceuticals)	acute myeloid leukemia	phase 3
crenolanib (CP-868-596, AROG Pharmaceuticals)	acute myeloid leukemia, gastrointestinal stromal tumor, glioma	phase 2
crizotinib (Xalkori, Pfizer)	non-small cell lung cancer	phase 3
CRLX101 (Cerulean Pharma)	solid tumors	phase 2
croliulin (EpiCept)	solid tumors	phase 2
CRS-207 (GVAX Pancreas, Aduro BioTech)	pancreatic cancer	phase 2
CT-011 (Cure Tech)	colorectal cancer	phase 2
CTL019 (Novartis)	chronic lymphocytic leukemia	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
custirsen (OncoGenex Pharmaceuticals/Teva Pharmaceuticals)	non-small cell lung cancer/prostate cancer	phase 2/phase 3
CV-301 breast (Bavarian Nordic)	metastatic breast cancer	phase 2
CV-301 colon (Bavarian Nordic)	colon cancer	phase 2
dabrafenib (Tafinlar, GlaxoSmithKline)	colorectal cancer, non-small cell lung cancer/melanoma	phase 2/phase 3
dacomitinib (PF-00299804, Pfizer)	non-small cell lung cancer	phase 3
dalantercept (ACE-041, Accerlon Pharma)	head and neck cancers	phase 2
dalotuzumab (MK-0646, Merck)	cancer	phase 2
darbepoetin alfa (Aranesp, Amgen)	myelodysplastic syndrome	phase 3
darinaparsin (ZIO-101, Ziopharm Oncology)	hematologic malignancies, liver cancer, myeloma	phase 2
dasatinib (Sprycel, Bristol-Myers Squibb)	breast cancer, glioblastoma, leukemia, pancreatic cancer, prostate cancer	phase 2
dasiprotimut-T (BiovaxID, Biovax International)	mantle cell lymphoma/follicular lymphoma	phase 2/phase 3
DCVax-Brain (Northwest Biotherapeutics)	brain cancer	phase 3
DCVax-Direct (Northwest Biotherapeutics)	inoperable solid tumors	phase 2
DCVax-L (Northwest Biotherapeutics)	glioblastoma	phase 3
DCVax-Prostate (Northwest Biotherapeutics)	prostate cancer	phase 3
decitabine (Dacogen, Eisai)	pediatric acute myeloid leukemia	phase 2
degarelix (ASP3550, Astellas)	prostate cancer	phase 3
delanzomib (Cephalon)	myeloma	phase 2
dendritic cell vaccine (GMB-Vax, Activartis Biotech)	glioblastoma	phase 2
dendritic cell vaccine (Quantum Immunologics)	breast cancer	phase 2
denileukin diftitox (Ontak, Eisai)	melanoma	phase 2
denosumab (Xgeva, Amgen)	hypercalcemia of malignancy, non-small cell lung cancer/breast cancer, delay or prevention of bone metastases in breast cancer, cancer-related bone damage in multiple myeloma	phase 2/phase 3
DFP-10917 (Delta-Fly Pharma)	acute lymphoblastic leukemia, acute myeloid leukemia	phase 2
DI17E6 (EMD Serono)	colorectal cancer, prostate cancer	phase 2
dimesna (Tavocept, BioNumerik Pharmaceuticals)	lung cancer	phase 3
DN24-02 (Dendreon)	HER-2-positive urogenital cancer	phase 2
dorgenmeltucel-L (HyperAcute Melanoma, NewLink Genetics)	melanoma	phase 2
doxorubicin liposomal (Myocet, Sopherion Therapeutics)	breast cancer	phase 3
doxorubicin liposomal (ThermoDox, Celsion)	breast cancer, colorectal cancer/liver cancer	phase 2/phase 3
DPV-001 (UbiVac)	non-small cell lung cancer	phase 2
DPX-0907 (Immunovaccine)	breast cancer, ovarian cancer, prostate cancer	phase 2
DPX-Survivac (Immunovaccine)	ovarian cancer	phase 2
dronabinol oral solution (INSYS Therapeutics)	chemotherapy-induced nausea and vomiting	phase 3
E7016 (Eisai)	melanoma	phase 2
E7040 (DC Bead, Eisai)	transcatheter arterial embolization of hypervascular tumors	phase 3

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
E75 cancer vaccine (NeuVax, Galena Biopharma)	breast cancer (node-negative), prostate cancer/breast cancer (node-positive)	phase 2/phase 3
E7820 (Eisai)	colorectal cancer	phase 2
ecromeximab (Life Science Pharmaceuticals)	melanoma	phase 2
EGEN-001 (Expression Genetics)	colorectal cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer	phase 2
elagolix (Abbott Laboratories/Neurocrine Biosciences)	uterine leiomyoma	phase 2
elesclomol (Synta Pharmaceuticals)	non-small cell lung cancer, ovarian cancer	phase 2
elotuzumab (AbbVie/Bristol-Myers Squibb)	myeloma	phase 3
eltrombopag (Promacta, GlaxoSmithKline)	acute myeloid leukemia, aplastic anemia, myelodysplastic syndrome	phase 2
EN3488 (Endo Pharmaceuticals)	bladder cancer	phase 3
encapsulated cell therapy (Rogosin Institute)	colorectal cancer, pancreatic cancer, prostate cancer	phase 2
eniluracil (Adherex Technologies)	breast cancer	phase 2
ENMD-2076 (EntreMed)	breast cancer, ovarian cancer, soft tissue sarcoma	phase 2
ensituximab (Precision Biologics)	pancreatic cancer	phase 2
entinostat (Syndax Pharmaceuticals)	breast cancer, colorectal cancer, kidney cancer, leukemia, non-small cell lung cancer, relapsed or refractory Hodgkin's lymphoma	phase 2
enzalutamide (Xtandi; Astellas, Medivation)	breast cancer/prostate cancer	phase 2/phase 3
EP-2101 (Biotech Synergy)	non-small cell lung cancer	phase 2
epratuzumab (Immunomedics)	leukemia, lymphoma	phase 2
eribulin mesylate (Halaven, Eisai)	breast cancer, non-small cell lung cancer, sarcoma	phase 3
erismodegib (LDE225, Novartis)	acute leukemia, basal cell carcinoma, breast cancer, myelofibrosis, pancreatic cancer/medulloblastoma	phase 2/phase 3
erlotinib (Tarceva; Genentech, Astellas)	non-small cell lung cancer, pediatric ependymoma	phase 3
ETBX-011 (Etubics)	colorectal cancer	phase 2
etirinotecan pegol (NKTR-102, Nektar Therapeutics)	ovarian cancer/breast cancer, colorectal cancer	phase 2/phase 3
everolimus (Afinitor, Novartis)	breast cancer, diffuse large B-cell lymphoma	phase 3
ezatiostat (Telik)	myelodysplastic syndrome	phase 2
EZN-2208 (Enzon Pharmaceuticals)	breast cancer, colorectal cancer, solid tumors	phase 2
farletuzumab (MORAb-003, Eisai)	non-small cell lung cancer/ovarian cancer	phase 2/phase 3
FBP vaccine (Galena Biopharma)	endometrial cancer, ovarian cancer	phase 2
fentanyl inhalation (Akela Pharma)	cancer pain	phase 3
FG-3019 (FibroGen)	pancreatic cancer	phase 2
ficlatuzumab (AV-299, AVEO Pharmaceuticals)	non-small cell lung cancer	phase 2
filanesib (ARRY-520, Array BioPharma)	myeloma	phase 2
fluciclatide F-18 (GE Healthcare/NCI)	solid tumors	phase 2
folate-binding protein vaccine (E39, Galena Biopharma)	endometrial cancer, ovarian cancer	phase 2
foretinib (GlaxoSmithKline)	non-small cell lung cancer	phase 2
forodesine (BioCryst Pharmaceuticals/Mundipharma)	chronic lymphocytic leukemia, T-cell non-Hodgkin's lymphoma	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
fosbretabulin (Zybrestat, Oxigene)	non-small cell lung cancer, ovarian cancer	phase 2
fulranumab (Johnson & Johnson)	cancer pain	phase 2
G-100 prophage cancer vaccine (Agenus)	newly diagnosed glioma	phase 2
G-200 prophage cancer vaccine (Agenus)	recurrent glioma	phase 2
G-202 (GenSpera)	hepatocellular carcinoma	phase 2
G-series prophage vaccine (Agenus)	glioma	phase 2
ganetespib (Hsp90i, Synta Pharmaceuticals)	breast cancer, colorectal cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, liver cancer, melanoma, pancreatic cancer, prostate cancer/non-small cell lung cancer	phase 2/phase 3
GI-4000 (Globelimmune)	colorectal cancer, non-small cell lung cancer, pancreatic cancer	phase 2
GI-6207 (Globelimmune)	medullary thyroid cancer	phase 2
girentuximab (Rencarex, Wilex)	clear-cell renal cell carcinoma	phase 3
GL-0810 (GliKnik)	head and neck squamous cell carcinoma	phase 2
GL-0817 (GliKnik)	head and neck cancers, myeloma	phase 2
GliAtak (Advantagene)	brain tumors	phase 2
glufosfamide (Eleison Pharmaceuticals)	pancreatic cancer	phase 3
GM-CT-01 (Galectin Therapeutics)	colorectal cancer	phase 2
golnerminogene pradenovec (TNFerade, GenVec)	esophageal cancer, head and neck cancers, melanoma	phase 2
GRN1005 (Geron)	brain metastases	phase 2
GRNVAC 1 (Geron)	acute myeloid leukemia, prostate cancer	phase 2
GS-9973 (Gilead)	hematologic malignancies	phase 2
GTx-758 (GTx)	prostate cancer	phase 2
GVAX Pancreatic (BioSante Pharmaceuticals/Aduro BioTech)	pancreatic cancer	phase 2
GVAX Prostate (BioSante Pharmaceuticals/Aduro BioTech)	prostate cancer	phase 3
HE3235 (Harbor Therapeutics)	prostate cancer	phase 2
histamine dihydrochloride (Ceplene, EpiCept)	acute myeloid leukemia	phase 3
HS-110 (Heat Biologics)	non-small cell lung cancer	phase 2
HSC835 (Novartis)	stem cell transplantation	phase 2
hTERT RNA vaccine (BioTime)	acute myeloid leukemia	phase 2
hydromorphone (Daiichi-Sankyo)	cancer pain	phase 3
HyperAcute Prostate (NewLink Genetics)	prostate cancer	phase 2
I-124-CLR1404 (Cellecstar Biosciences)	glioblastoma, solid tumors	phase 2
I-131-CLR1404 (Cellecstar Biosciences)	solid tumors	phase 2
ibrutumomab tiuxetan (Spectrum Pharmaceuticals)	diffuse large B-cell lymphoma	phase 3
ibrutinib (Janssen/PharmacyClics)	follicular lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia/diffuse large B-cell lymphoma	phase 2/phase 3
icrucumab (LY3012212/IMC-18F1; Eli Lilly, ImClone)	cancer	phase 2
ICT-107 (ImmunoCellular Therapeutics)	glioblastoma, glioma	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
idelalisib (Gilead)	chronic lymphocytic leukemia, myelofibrosis, non-Hodgkin's lymphoma	phase 3
IDM-2101 (Biotech Synergy)	non-small cell lung cancer	phase 2
IMA901 (immatics biotechnologies)	renal cell carcinoma	phase 3
imetelstat (Geron)	breast cancer, essential thrombocythemia, myeloma, non-small cell lung cancer	phase 2
IMGN901 (ImmunoGen)	small cell lung cancer	phase 2
IMO-2055 (Idera Pharmaceuticals)	head and neck cancers	phase 2
Imprime PGG (Biothera)	chronic lymphocytic leukemia, non-small cell lung cancer/colorectal cancer, non-Hodgkin's lymphoma	phase 2/phase 3
INCB24360 (Incyte)	melanoma, ovarian cancer	phase 2
INCB28060 (Incyte)	hepatocellular carcinoma, non-small cell lung cancer, solid tumors	phase 2
INCB39110 (Incyte)	myelofibrosis	phase 2
indibulin (ZIO-301, Ziopharm Oncology)	breast cancer	phase 2
indoximod (NewLink Genetics)	breast cancer, prostate cancer	phase 2
ingenol mebutate (Picato, Leo Pharma)	basal cell cancer	phase 2
INNO-206 (CytRx)	pancreatic ductal adenocarcinoma, soft tissue sarcoma, solid tumors	phase 2
inotuzumab ozogamicin (Pfizer)	acute lymphoblastic leukemia	phase 3
interleukin-12 gene therapy (OncoSec Medical)	cutaneous T-cell lymphoma, melanoma, merkel cell carcinoma	phase 2
intradermal cancer vaccine (CVac, Prima Biomed)	ovarian cancer	phase 3
iobenguane I-131 (Azedra, Progenics)	neuroendocrine tumors	phase 2
ipatasertib (GDC-0068/RG7440; Genentech, Array BioPharma)	solid tumors	phase 2
IPI-145 (Infinity Pharmaceuticals)	follicular lymphoma	phase 2
ipilimumab (Yervoy, Bristol-Myers Squibb)	cervical cancer, melanoma, prostate cancer/lung cancer	phase 2/phase 3
irinotecan-eluting beads (Biocompatibles International)	liver metastases from colorectal cancer	phase 2
IRX-2 (IRX Therapeutics)	head and neck squamous cell carcinoma	phase 2
IRX4204 (Io Therapeutics)	prostate cancer	phase 2
ISF34 (Memgen)	chronic lymphocytic leukemia, non-Hodgkin's lymphoma	phase 2
ISF35 (Memgen)	chronic lymphocytic leukemia, non-Hodgkin's lymphoma	phase 2
ISIS-EIF4ERx (Isis Pharmaceuticals)	non-small cell lung cancer, prostate cancer	phase 2
ixazomib citrate (MLN9708, Millennium Pharmaceuticals)	amyloidosis, multiple myeloma	phase 3
JI-101 (Jubilant Biosys)	solid tumors	phase 2
JNJ-56021927/ARN-509 (Janssen)	prostate cancer	phase 3
KD019 (Kadmon Pharmaceuticals)	non-small cell lung cancer	phase 3
KD032 (Kadmon Pharmaceuticals)	non-small cell lung cancer, pancreatic cancer	phase 2
KRN-330 (Kyowa Hakko Kirin Pharma)	colorectal cancer	phase 2
KX2-391 (Kinex Pharmaceuticals)	prostate cancer	phase 2
KW-2450 (Kyowa Hakko Kirin Pharma)	breast cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
KW-2478 (Kyowa Hakko Kirin)	myeloma	phase 2
Ianreotide acetate (Somatuline, Ipsen Biopharmaceuticals)	neuroendocrine tumors	phase 3
Iansoprazole (Apricus Biosciences)	liver cancer	phase 2
lapatanib (Tykerb, GlaxoSmithKline)	breast cancer	phase 3
LDK378 (Novartis)	non-small cell lung cancer	phase 3
LEE011 (Novartis)	breast cancer, melanoma, solid tumors	phase 2
Ienalidomide (Revlimid, Celgene)	acute myeloid leukemia, adult T-cell leukemia-lymphoma, mantle cell lymphoma/chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, indolent lymphoma, multiple myeloma, myelodysplastic syndrome	phase 2/phase 3
Ienvatinib (E7080, Eisai)	endometrial cancer, glioma, melanoma, non-small cell lung cancer/hepatocellular cancer, thyroid cancer	phase 2/phase 3
Iestaurtinib (CEP-701, Cephalon)	acute myeloid leukemia, myeloproliferative disorders	phase 2
leukocyte interleukin (Multikine, CEL-SCI)	head and neck squamous cell carcinoma	phase 3
LGX818 (Novartis)	colorectal cancer, solid tumors/melanoma	phase 2/phase 3
linifanib (Abbott Laboratories)	breast cancer, colorectal cancer, non-small cell lung cancer, renal cancer/liver cancer	phase 2/phase 3
Iinsitinib (ASP7487, Astellas)	ovarian cancer	phase 2
Iintuzumab Ac-225 (Actimab-A, Actinium)	acute myeloid leukemia	phase 2
Iintuzumab Bi-213 (Bismab-A, Actinium)	acute myeloid leukemia	phase 2
Iiposome encapsulated paclitaxel (Insys Therapeutics)	breast cancer	phase 2
Iiposome entrapped docetaxel (LE-DT, Insys Therapeutics)	pancreatic cancer	phase 2
LJM716 (Novartis)	esophageal squamous cell carcinoma	phase 2
Iobenguane I-131 (Ultratrac MIBG, Molecular Insight Pharmaceuticals)	neuroendocrine tumors	phase 2
LOR-2040 (Lorus Therapeutics)	acute myeloid leukemia, breast cancer, colorectal cancer, prostate cancer, renal cancer	phase 2
Iorvotuzumab mertansine (ImmunoGen)	small cell lung cancer	phase 2
LY2090314 (Eli Lilly)	cancer	phase 2
LY2157299 (Eli Lilly)	brain cancer, liver cancer	phase 2
LY2228820 (Eli Lilly)	cancer	phase 2
LY2510924 (Eli Lilly)	cancer	phase 2
LY2606368 (Eli Lilly)	cancer	phase 2
LY2784544 (Eli Lilly)	myeloproliferative neoplasms	phase 2
LY2801653 (Eli Lilly)	cancer	phase 2
LY2812176 (Eli Lilly)	cancer	phase 2
LY2835219 (Eli Lilly)	cancer	phase 2
LY2874455 (Eli Lilly)	cancer	phase 2
LY2875358 (Eli Lilly)	cancer	phase 2
LY2940680 (Eli Lilly)	cancer	phase 2
Iyso-thermosensitive liposomal doxorubicin (Celsion)	hepatocellular carcinoma	phase 3

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
M-200 prophage cancer vaccine (Agenus)	melanoma	phase 3
M402 (Momenta Pharmaceuticals)	pancreatic cancer	phase 2
MAGE-A3 antigen-specific cancer immunotherapeutic (Glaxo-SmithKline)	bladder cancer/melanoma, non-small cell lung cancer	phase 2/phase 3
MB07133 (Ligand Pharmaceuticals)	liver cancer	phase 2
MEDI4736 (AstraZeneca/MedImmune)	locally-advanced, metastatic non-small cell lung cancer	phase 2
MEDI-551 (MedImmune)	chronic lymphocytic leukemia, diffuse large B-cell lymphoma	phase 2
MEDI-573 (MedImmune)	hormone-sensitive metastatic breast cancer	phase 2
masitinib (AB1010, AB Science)	gastrointestinal stromal tumors, pancreatic cancer	phase 3
MEK162 (Novartis)	biliary tract carcinoma, gastrointestinal stromal tumors, solid tumors/fallopian tube cancer, melanoma, ovarian cancer, peritoneal cancer	phase 2/phase 3
melapuldencel-T (California Stem Cell)	melanoma	phase 2
mepacrine (CBLC102; Cleveland BioLabs, Incuron)	prostate cancer	phase 2
MER-101 (Merrion Pharmaceuticals)	bone metastases	phase 2
MGCD265 (MethylGene)	non-small cell lung cancer	phase 2
midostaurin (PKC412, Novartis)	acute myeloid leukemia	phase 3
miliclib (Nerviano Medical Sciences)	thymic epithelial tumors	phase 2
MK-2206 (Merck)	cancer	phase 2
MK-3475 (Merck)	non-small cell lung cancer/melanoma	phase 2/phase 3
MM-111 (Merrimack Pharmaceuticals)	breast cancer, HER-2-positive adenocarcinoma of the stomach and gastroesophageal junction, HER-2-positive adenocarcinoma of the esophagus	phase 2
MM-398 (Merrimack Pharmaceuticals)	pancreatic cancer	phase 3
mocetinostat (MGCD0103, MethylGene)	diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma, solid tumors	phase 2
mogamulizumab (Kyowa Hakko Kirin)	adult T-cell leukemia, adult T-cell lymphoma, peripheral T-cell lymphoma/cutaneous T-cell lymphoma	phase 2/phase 3
momelotinib (Gilead)	myelofibrosis	phase 3
monoclonal antibody TNT-1 (Cotara, Peregrine Pharmaceuticals)	glioblastoma	phase 2
MORAb-004 (Eisai)	colorectal cancer, melanoma, soft tissue sarcoma	phase 2
morphine intranasal (Marina Biotech)	cancer pain	phase 2
moxetumomab pasudotox (MedImmune)	hairy cell leukemia	phase 3
MUC-1 cancer vaccine (CVac, Prima Biomed)	late-stage ovarian cancer	phase 3
muparfostat (PI-88, Progen Pharmaceuticals)	melanoma/liver cancer	phase 2/phase 3
MVA-BN HER2 (Bavarian Nordic)	breast cancer	phase 2
MVA-BN PRO (Bavarian Nordic)	prostate cancer	phase 2
MVAX (AVAX Technologies)	melanoma	phase 3
nabiximols (Otsuka America Pharmaceutical)	cancer pain	phase 3
necitumumab (IMC-11F8; Bristol-Myers Squibb, Eli Lilly, ImClone Systems)	non-small cell lung cancer	phase 3
neratinib (PB272, Puma Biotechnology)	breast cancer	phase 2
netupitant-palonosetron (Helsinn Therapeutics)	chemotherapy-induced nausea and vomiting	phase 3

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
NGF-hTNF (MolMed)	malignant pleural mesothelioma	phase 3
NGR-hTNF (MolMed)	mesothelioma	phase 3
nilotinib (Tasigna, Novartis)	acute myeloid leukemia, chronic myeloid leukemia	phase 2
nimotuzumab (Daiichi-Sankyo)	gastric cancer, non-small cell lung cancer	phase 3
nintedanib (Boehringer Ingelheim)	ovarian cancer	phase 3
niraparib (Tesarco)	ovarian cancer	phase 3
nivolumab (Bristol-Myers Squibb)	melanoma	phase 3
NK012 (Nippon Kayaku)	breast cancer, small cell lung cancer	phase 2
NP-2 gene therapy (Diamyd Medical)	cancer pain	phase 2
NS-018 (Nippon Shinyaku)	myelofibrosis	phase 2
NTX-010 (Neotropix)	small cell lung cancer	phase 2
NX101 (NexGenix)	dermal neurofibromatosis	phase 2
NX-1207 (Nymox Pharmaceutical)	prostate cancer	phase 2
NV1020 (Catherex)	liver cancer	phase 2
obinutuzumab (GA 101; Biogen Idec, Genentech)	chronic lymphocytic leukemia, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma	phase 3
ocaratuzumab (AME-133v, Mentrik Biotech)	follicular lymphoma, non-Hodgkin's lymphoma	phase 2
ODM-201 (Endo Pharmaceuticals/Orion)	prostate cancer	phase 2
olaparib (AstraZeneca)	breast cancer/ovarian cancer	phase 2/phase 3
olaratumab (LY3012207; Eli Lilly, ImClone Systems)	non-small cell lung cancer	phase 2
omacetaxine mepesuccinate (Synribo, Teva)	myelodysplastic syndrome	phase 2
onartuzumab (Genentech)	colorectal cancer, non-small cell lung cancer/gastric cancer, non-small cell lung cancer	phase 2/phase 3
OncoVAX (Vaccinogen)	colorectal cancer	phase 2
Onyvax-105 (VaxOnco)	prostate cancer	phase 2
Onyvax-P (VaxOnco)	prostate cancer	phase 2
oprozomib (Amgen)	hematologic malignancies	phase 2
OPT-822 (Optimer Pharmaceuticals)	breast cancer	phase 2/phase 3
oregovomab (Quest PharmaTech)	ovarian cancer	phase 2
orteronel (TAK-700, Millennium)	prostate cancer	phase 3
OSE2101 (OSE Pharma)	non-small cell lung cancer	phase 3
OSI-027 (OSI Pharmaceuticals)	renal cancer	phase 2
otlertuzumab (Emergent BioSolutions)	chronic lymphocytic leukemia	phase 2
ovarian cancer mAb vaccine (MabVax Therapeutics)	ovarian cancer	phase 2
ozarelix (Spectrum Pharmaceuticals)	prostate cancer	phase 2
paclitaxel poliglumex (Opaxio, Cell Therapeutics)	esophageal cancer, glioblastoma, glioma/fallopian tube cancer, non-small cell lung cancer, ovarian cancer, peritoneal cancer	phase 2/phase 3
paclitaxel polymeric micelle formulation (Samyang Biopharmaceuticals)	pancreatic cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
paclitaxel protein-bound particles for injection suspension (Abraxane, Celgene)	melanoma, pancreatic cancer	phase 3
pacritinib (Cell Therapeutics)	relapsed lymphoma/myelofibrosis, myeloproliferative disorders with <i>JAK2 V617F</i> mutation	phase 2/phase 3
palbociclib (PD-0332991, Pfizer)	breast cancer	phase 3
palifosfamide (ZIO-201, Ziopharm Oncology)	sarcoma	phase 3
panitumumab (Vectibix, Amgen)	colorectal cancer	phase 3
panobinostat (LBH589, Novartis)	prostate cancer, renal cancer/multiple myeloma	phase 2/phase 3
patritumab (Daiichi-Sankyo)	breast cancer, non-small cell lung cancer	phase 2
pazopanib (Votrient, GlaxoSmithKline)	renal cell cancer	phase 3
PCI-27483 (Pharmacyclics)	pancreatic cancer	phase 2
PEG arginine deiminase (Polaris Pharmaceuticals)	melanoma/hepatocellular carcinoma	phase 2/phase 3
pegylated recombinant human hyaluronidase (PEGPH20, Halozyme Therapeutics)	pancreatic cancer	phase 2
perifosine (Aeterna Zentaris)	chronic lymphocytic leukemia, gastrointestinal stromal tumor, glioma, non-small cell lung cancer, renal cancer, sarcoma/colorectal cancer	phase 2/phase 3
personalized cancer vaccine (Reximmune-C, Epeius Biotechnologies)	breast cancer	phase 2
pertuzumab (Perjeta, Genentech)	gastric cancer/breast cancer	phase 2/phase 3
pexastimogene devacirepvec (JX-594, Jennerex)	colorectal cancer, hepatocellular carcinoma	phase 2
PF-03446962 (Pfizer)	hepatocellular carcinoma	phase 2
PF-04449913 (Pfizer)	acute myeloid leukemia	phase 2
PF-05212384 (Pfizer)	colorectal cancer	phase 2
PF-05280014 (Pfizer)	breast cancer	phase 3
PHA-848125 (Nerviano Medical Services)	thymic carcinoma	phase 2
phenoxodiol (Marshall Edwards)	fallopian tube cancer, prostate cancer/ovarian cancer	phase 2/phase 3
PHY906 (PhytoCeutica)	chemotherapy-induced gastrointestinal disorders, colorectal cancer, liver cancer, pancreatic cancer	phase 2
picoplatin (Poniard Pharmaceuticals)	colorectal cancer, ovarian cancer, prostate cancer, small cell lung cancer	phase 2
pictilisib (GDC-0941/RG7321, Genentech)	solid tumors	phase 2
pidilizumab (CT-011, CureTech)	diffuse large B-cell lymphoma	phase 2
pimasertib (EMD Serono)	melanoma, pancreatic cancer	phase 2
pinatuzumab vedotin (DCDT2980S/RG7593, Genentech)	diffuse large B-cell lymphoma, non-Hodgkin's lymphoma	phase 2
pixantrone (Pixuvri, Cell Therapeutics)	breast cancer/diffuse large B-cell lymphoma, follicular lymphoma	phase 2/phase 3
plinabulin (NPI-2358, Nereus Pharmaceuticals)	non-small cell lung cancer	phase 2
plitidepsin (Aplidin, PharmaMar)	myeloma	phase 3
PLX3397 (Daiichi-Sankyo)	acute myeloid leukemia, glioblastoma, Hodgkin's lymphoma, prostate cancer	phase 2
PM00104 (PharmaMar)	cervical cancer, endometrial cancer, Ewing's sarcoma	phase 2
PNT2258 (ProNAi Therapeutics)	B-cell lymphoma	phase 2
POL-103A (Polynoma)	melanoma	phase 3
polatuzumab vedotin (Genentech)	diffuse large B-cell lymphoma, non-Hodgkin's lymphoma	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
Poly-ICLC (Emory University/Oncovir/University of California)	anaplastic astrocytoma, glioblastoma	phase 2
polyclonal antibody stimulator (Cancer Advances)	colorectal cancer/gastric cancer, pancreatic cancer	phase 2/phase 3
ponatinib (Iclusig, Ariad)	Ph+ acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, lung cancer, medullary thyroid cancer	phase 2
PR-104 (Proacta)	acute myeloid leukemia	phase 2
pracinostat (MEI Pharma)	myelodysplastic syndrome, myelofibrosis	phase 2
pralatrexate (Folotyn, Spectrum)	peripheral T-cell lymphoma	phase 2
PRAME immunotherapeutic (GlaxoSmithKline)	non-small cell lung cancer	phase 3
PRI-724 (Prism Pharma)	acute myeloid leukemia, chronic myeloid leukemia	phase 2
PRLX 93936 (Prolexsys Pharmaceuticals)	myeloma	phase 2
prophage cancer vaccine (Oncophage, Agenus)	renal cell carcinoma	phase 3
propranolol (Pierre Fabre)	infantile hemangioma	phase 3
ProstAtak (Advantagene)	prostate cancer	phase 3
PRX302 (Sophiris Bio)	prostate cancer	phase 2
PT-107 (Pique Therapeutics)	non-small cell lung cancer	phase 2
PTC299 (PTC Therapeutics)	breast cancer, central nervous system tumors in children, solid tumors	phase 2
PV-10 (Provectus)	melanoma	phase 2
PV701 (Wellstat Biologics)	cervical cancer, colorectal cancer	phase 2
PVX-410 (OncoPep)	smoldering myeloma	phase 2
PX-866 (Oncothyreon)	glioblastoma, head and neck cancers, non-small cell lung cancer, prostate cancer	phase 2
quizartinib (Ambit Biosciences)	relapsed or refractory acute myeloid leukemia	phase 2
radium Ra 223 dichloride (Xofigo, Bayer HealthCare)	castration-resistant prostate cancer	phase 3
ranpirnase (Tamir Biotechnology)	non-small cell lung cancer	phase 2
refametinib (BAY 86-9766, Bayer HealthCare)	liver cancer, pancreatic cancer	phase 2
regorafenib (Stivarga; Bayer HealthCare, Onyx)	colorectal cancer, hepatocellular carcinoma	phase 3
remestemcel-L (Prochymal, Osiris Therapeutics)	graft-versus-host disease	phase 3
reovirus (Reolysin, Oncolytics Biotech)	glioma, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, sarcoma/head and neck cancers	phase 2/phase 3
retaspimycin (Infinity Pharmaceuticals)	non-small cell lung cancer	phase 2
Rexin-G (Epeius Biotechnologies)	breast cancer, osteosarcoma, pancreatic cancer, soft tissue sarcoma	phase 2
RG1273 (Roche)	gastric cancer	phase 3
RG7446 (Roche)	non-small cell lung cancer, renal cell cancer	phase 2
RG7593 (Roche)	hematologic malignancies	phase 2
RG7596 (Roche)	hematologic malignancies	phase 2
RG7597 (Roche)	epithelial tumors	phase 2
RG7601 (Roche)	chronic lymphocytic leukemia monotherapy/chronic lymphocytic leukemia combination therapy	phase 2/phase 3
RG7686 (Roche)	liver cancer	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
RG7853 (Roche)	non-small cell lung cancer	phase 2
RGI-2001 (REGiMMUNE)	graft-versus-host disease	phase 2
rigosertib (Estybon, Onconova Therapeutics)	ovarian cancer/myelodysplastic syndrome, pancreatic cancer	phase 2/phase 3
rilimogene galvacirepvec (Prostvac, Bavarian Nordic)	prostate cancer	phase 3
rilotumumab (Amgen)	gastric cancer	phase 3
rindopepimut (Celldex Therapeutics)	recurrent glioblastoma/first-line glioblastoma	phase 2/phase 3
rintatolimod (Hemispherx Biopharma)	cancer vaccine adjuvant	phase 2
rolapitant (Tesarco)	chemotherapy-induced nausea and vomiting	phase 3
romidepsin (Istodax, Celgene)	peripheral T-cell lymphoma	phase 3
RP101 (RESprotect)	pancreatic cancer	phase 3
rucaparib (Clovis Oncology)	breast cancer, ovarian cancer	phase 2
ruxolitinib (Jakafi, Incyte)	pancreatic cancer/polycythemia vera	phase 2/phase 3
RX-0201 (Archexin, Rexahn Pharmaceuticals)	pancreatic cancer	phase 2
S-1 (Taiho Pharma)	gastric cancer	phase 3
salirasib (Kadmon)	pancreatic cancer	phase 2
samarium SM-153 lexidronam injection (EUSA Pharma)	breast cancer, osteosarcoma, prostate cancer/bone metastases	phase 2/phase 3
sapacitabine (Cyclacel Pharmaceuticals)	chronic lymphocytic leukemia, myelodysplastic syndrome, non-small cell lung cancer/acute myeloid leukemia	phase 2/phase 3
SAR245409 (XL765; Exelixis, Sanofi)	ovarian cancer combination therapy	phase 2
SAR256212 (MM-121; Merrimack Pharmaceuticals, Sanofi)	breast cancer	phase 2
SAR3419 (ImmunoGen/Sanofi)	acute lymphoblastic leukemia, non-Hodgkin's lymphoma	phase 2
sarcoma mAb vaccine (MabVax Therapeutics)	sarcoma	phase 2
saridegib (Infinity Pharmaceuticals)	chondrosarcoma	phase 2
SBG (Biotec Pharmacon)	neuroblastoma	phase 2
seliciclib (CYC202, Cyclacel Pharmaceuticals)	nasopharyngeal cancer	phase 2
selumetinib (AZD6244/ARRY-142886; AstraZeneca, Array BioPharma)	various cancers/non-small cell lung cancer	phase 2/phase 3
SF1 (SonneMed)	breast cancer	phase 2
SG2000 (Spirogen)	ovarian cancer	phase 2
SGI110 (Astex Pharmaceuticals)	acute myeloid leukemia, liver cancer, myelodysplastic syndrome, ovarian cancer	phase 2
SGN-CD19A (Seattle Genetics)	acute lymphoblastic leukemia, non-Hodgkin's lymphoma	phase 2
SGN-CD33A (Seattle Genetics)	acute myeloid leukemia	phase 2
SGN-LIV1A (Seattle Genetics)	breast cancer	phase 2
siltuximab (Janssen)	multiple myeloma	phase 2
simtuzumab (Gilead)	colorectal cancer, myelofibrosis, pancreatic cancer	phase 2
sipuleucel-T (Provenge, Dendreon)	early-stage prostate cancer/recurrent early-stage prostate cancer	phase 2/phase 3
SL-401 (Stemline Therapeutics)	relapsed or refractory acute myeloid leukemia, relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
SL-701 (Stemline Therapeutics)	glioma	phase 2
SNSO1-T (Senesco Technologies)	diffuse large B-cell lymphoma, mantle cell lymphoma, myeloma	phase 2
sorafenib (Nexavar; Bayer, Onyx)	breast cancer	phase 3
sotatercept (ACE-011; Acceleron Pharma, Celgene)	anemia in myelodysplastic syndrome	phase 2
SP1049C (Supratek Pharma)	gastric cancer	phase 2
SPI-1620 (Spectrum Pharmaceuticals)	biliary cancer, non-small cell lung cancer	phase 2
SPI-2012 (Spectrum Pharmaceuticals)	chemotherapy-induced neutropenia	phase 2
squalamine (Ohr Pharmaceutical)	ovarian cancer	phase 2
SR 16234 (SRI International)	breast cancer	phase 2
sunitinib (Sutent, Pfizer)	renal cell carcinoma	phase 3
Sym004 (EMD Serono)	head and neck squamous cell carcinoma	phase 2
talactoferrin alfa (Agennix)	non-small cell lung cancer	phase 3
talaporfin (Aptocine, Light Sciences Oncology)	colorectal cancer	phase 3
talimogene laherparepvec (Amgen)	melanoma	phase 3
tamibarotene (CytRx)	acute promyelocytic leukemia, non-small cell lung cancer	phase 2
TAS-106 (Taiho Pharma)	head and neck cancers	phase 2
tasquinimod (Active Biotech)	prostate cancer	phase 3
TC-99m ethylenedicycysteine glucosamine (Cell Point)	non-small cell lung cancer diagnosis	phase 3
TC-99m tilmanocept (Lymphoseek, Navidea Pharmaceuticals)	head and neck cancer diagnosis	phase 3
tecemotide (L-BLP25; EMD Serono)	non-small cell lung cancer	phase 3
technetium Tc-99m etarfolatide (EC20, Endocyte)	non-small cell lung cancer/ovarian cancer	phase 2/phase 3
tegafur/gimeracil/oteracil (Taiho Pharma)	gastric cancer	phase 3
telapristone (Repros Therapeutics)	uterine leiomyoma	phase 2
telatinib (ACT Biotech)	gastric cancer	phase 2
terameprocol (Erimos Pharmaceuticals)	cervical intraepithelial neoplasia, glioma	phase 2
tergenpumatucl-L (HyperAcute Lung, NewLink Genetics)	non-small cell lung cancer	phase 2
tesetaxel (Genta)	bladder cancer, breast cancer, gastric cancer, melanoma, prostate cancer	phase 2
tetradecanoylphorbol acetate (Biosuccess Biotech)	acute myeloid leukemia	phase 2
TH-302 (EMD Serono/Threshold Pharmaceuticals)	soft tissue sarcoma, pancreatic cancer	phase 3
TH9402 (Kiadis Pharma)	graft-versus-host disease	phase 2
thymalfasin alfa 1 (Zadaxin, SciClone Pharmaceuticals)	liver cancer, melanoma	phase 3
tigapotide (Kotinos Pharmaceuticals)	prostate cancer	phase 2
tivantinib (ARQ 197; ArQule, Daiichi Sankyo)	colorectal cancer, germ cell and embryonal neoplasms, kidney cancer, liver cancer, soft tissue sarcoma/hepatocellular carcinoma, non-small cell lung cancer	phase 2/phase 3
tivozanib (Astellas Pharma/Aveo Pharmaceuticals)	breast cancer, colorectal cancer/renal cancer	phase 2/phase 3
TKI258 (Novartis)	breast cancer, endometrial cancer, melanoma, myeloma, prostate cancer, urothelial carcinoma/kidney cancer	phase 2/phase 3

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
TL32711 (TetraLogic Pharmaceuticals)	acute myelogenous leukemia, solid tumors	phase 2
TNT-1B mAB (Cotara, Peregrine Pharmaceuticals)	anaplastic astrocytoma, glioblastoma	phase 2
Toca 511 (Tocagen)	glioblastoma	phase 2
topotecan liposomes injection (Spectrum)	ovarian cancer, small cell lung cancer	phase 2
tosedostat (Cell Therapeutics/Chroma Therapeutics)	acute myeloid leukemia	phase 2
trabectedin (Yondelis, Janssen)	sarcoma, ovarian cancer	phase 3
trametinib (Mekinist, GlaxoSmithKline)	colorectal cancer/melanoma	phase 2/phase 3
trans sodium crocetinate (Diffusion Pharmaceuticals)	glioblastoma	phase 2
TRC 105 (Tracon Pharmaceuticals)	breast cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer, prostate cancer	phase 2
trebananib (AMG 386, Amgen)	ovarian cancer	phase 3
tremelimumab (MedImmune)	unresectable pleural or peritoneal malignant mesothelioma	phase 2
trivalent ganglioside cancer vaccine (MabVax Therapeutics)	sarcoma	phase 2
TroVax (Oxford BioMedica)	prostate cancer	phase 2
TRU-016 (Emergent Biosolutions)	chronic lymphocytic leukemia	phase 2
tumor-targeted gene therapy (Rexin-G, Epeius Biotechnologies)	sarcoma	phase 2
TVA-Brain-1 (TVAX Biomedical)	central nervous system malignancies	phase 2
TVI-Brain-1 (TVAX Biomedical)	glioma	phase 2
TVI-Kidney-1 (TVAX Biomedical)	renal cell carcinoma	phase 2
TXA127 (Tarix Pharmaceuticals)	chemotherapy-induced thrombocytopenia	phase 2
ublituximab (TG-1101, TG Therapeutics)	chronic lymphocytic leukemia, extranodal marginal zone lymphoma, nodal marginal zone lymphoma, non-Hodgkin's lymphoma	phase 2
ulipristal acetate (Fibristal, Actavis)	uterine leiomyoma	phase 3
Ultratrace lobenguane I 131 (Azedra, Progenics Pharmaceuticals)	neuroblastoma, paraganglioma, pheochromocytoma	phase 2
umbilical cord blood stem cell therapy (NiCord, Gamida Cell)	hematologic malignancies	phase 2
upamostat (WX-671, Wilex)	breast cancer	phase 2
uridine triacetate (PN401, Wellstat Therapeutics)	gastric cancer/pancreatic cancer	phase 2/phase 3
V503 (Merck)	HPV-related cancers, prevention of cervical cancer, prevention of vulvovaginal cancer	phase 3
VAL-083 (Del Mar Pharmaceuticals)	glioma	phase 2
vandetanib (Caprelsa, AstraZeneca)	medullary thyroid cancer	phase 3
VB4-845 (Viventia Biotech)	bladder cancer, head and neck squamous cell carcinoma	phase 2
VB-111 (Vascular Biogenics)	glioma, thyroid cancer	phase 2
velimogene aliplasmid (Allovectin, Vical)	melanoma	phase 3
veliparib (ABT-888, AbbVie)	BRCA-deficient breast cancer, colorectal cancer, fallopian tube cancer, melanoma, non-small cell lung cancer, ovarian cancer/triple-negative breast cancer	phase 2/phase 3
veltuzumab (Immunomedics)	non-Hodgkin's lymphoma	phase 2
vemurafenib (Zelboraf; Genentech, Daiichi Sankyo)	thyroid cancer/melanoma	phase 2/phase 3
VGX-3100 (Inovio Pharmaceuticals)	cervical dysplasia	phase 2

Oncology Drugs in the Pipeline

Generic name (Brand name, Manufacturer)	Indication(s)	Development status
vincristine sulfate liposome injection (Marqibo, Spectrum)	acute lymphoblastic leukemia, non-Hodgkin's lymphoma	phase 3
vinorelbine liposomes injection	breast cancer, lung cancer	phase 2
vintafolide (MK-8109, Merck)	ovarian cancer	phase 3
Virulizin (Lorus Therapeutics)	pancreatic cancer	phase 3
vismodegib (Erivedge; Genentech)	acute myeloid leukemia, basal cell carcinoma	phase 2
vitespen (Oncophage, Agenus)	renal cell carcinoma	phase 3
volasertib (Boehringer Ingelheim)	acute myeloid leukemia	phase 3
volociximab (Abbott Laboratories/Biogen Idec)	non-small cell lung cancer	phase 2
vosaroxin (Sunesis Pharmaceuticals)	ovarian cancer/acute myeloid leukemia	phase 2/phase 3
VS-6063 (Verastem)	mesothelioma	phase 2
VT-464 (Viamet Pharmaceuticals)	prostate cancer	phase 2
VTX-2337 (VentiRx; Celgene, Array BioPharmax)	head and neck cancers, ovarian cancer	phase 2
Xen2174 (Xenome)	cancer pain	phase 2
WT1 immunotherapeutic (GlaxoSmithKline)	breast cancer	phase 2
Y-90 clivatuzumab tetraxetan (Immunomedics)	pancreatic cancer	phase 2
zanolimumab (Emergent BioSolutions)	peripheral T-cell lymphoma	phase 2

Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HEMONC TODAY. The publisher or editors do not assume responsibility for any errors or omissions.